Pharmaceutical Sector Q4 Earnings Mixed; XPH ETF Posts 29% One-Year Return
Q4 earnings were mixed across 17 tracked pharmaceutical companies. Elanco and ANI Pharmaceuticals beat revenue estimates, while Corcept and Amphastar missed. The XPH pharma ETF posted a 29% one-year return but significantly lagged the S&P 500 over five and ten years.
The pharmaceutical sector delivered mixed fourth-quarter results, with revenues among 17 tracked companies missing analysts' consensus estimates by 0.7%, while next quarter's revenue guidance came in 0.6% above expectations. Share prices have held steady on average since the latest earnings reports.
Elanco Animal Health reported revenues of $1.14 billion, up 12.2% year on year, exceeding analysts' expectations by 4.8%. Despite the top-line beat, the quarter was mixed as the company missed analysts' EPS guidance for next quarter. The stock is down 9.2% since reporting and trades at $22.48.
ANI Pharmaceuticals posted revenues of $247.1 million, up 29.6% year on year, outperforming expectations by 6.9%. The company delivered a solid beat of revenue estimates and an impressive beat of full-year EPS guidance. The stock is up 3.8% since reporting, trading at $80.08.
Corcept Therapeutics reported revenues of $202.1 million, up 11.1% year on year, but fell short of analysts' expectations by 18.5%. It was a disappointing quarter with significant misses on both revenue and EPS estimates. The stock is up 27.7% since results, trading at $46.57.
Zoetis reported revenues of $2.39 billion, up 3% year on year, topping expectations by 0.8%. The company also logged an impressive beat of full-year EPS guidance estimates. The stock is down 8.8% since reporting, trading at $117.40.
Amphastar Pharmaceuticals reported revenues of $183.1 million, down 1.8% year on year, missing analysts' expectations by 2.5%. The stock is down 21% since reporting, trading at $20.93.
Looking ahead, growth in the pharmaceuticals sector is expected to be driven by innovations in precision medicine, such as genetic therapies and advanced biologics, and the increasing use of AI to speed drug discovery. The sector faces headwinds from bipartisan political pressure on drug pricing, scrutiny of patent practices, and growing competition from biosimilars.
The SPDR S&P Pharmaceuticals ETF (XPH), which holds 57 positions with relatively even weighting and no single stock exceeding 2.12% of the portfolio, posted a one-year return of 29.44%, significantly outpacing the S&P 500's 12% gain. However, over five years, XPH gained just 10.49% against the broader market's 74.77%, and over ten years, its cumulative return was dwarfed by the S&P 500's 255.65% gain. The ETF has a 0.35% expense ratio and a 0.48% dividend yield.